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Abstract
Over the last few years, taking advantage of the linear growth of diameter kinetics,
tumor diameter-based rather than tumor volume-based models have been devel-
oped for the phenomenological modeling of tumor growth. In this study, we propose
a new tumor diameter growth function composed of two linear parts and one ex-
ponential term to characterize early, late and steady-state treatment effects. Model
parameters consist of growth rates, growth delays and time constants and are mean-
ingful for biologists. Biological experiments provide in vivo longitudinal data. The
latter are analyzed using a mixed effects model based on the new diameter growth
function, to take into account inter-mouse variability and treatment factors. The rel-
evance of the tumor growth mixed model is firstly assessed by analyzing the effects
of three therapeutic strategies for cancer treatment (radiotherapy, concomitant ra-
diochemotherapy and photodynamic therapy) administered on mice. Then, effects of
the radiochemotherapy treatment duration are estimated within the mixed model.
The results highlight the model suitability for analyzing therapeutic efficiency, com-
paring treatment responses and optimizing, when used in combination with optimal
experiment design, anti-cancer treatment modalities.
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1 Introduction
In systems theory1,2, phenomenological or black-box models are holistic rep-
resentations of complex systems in nature, society, and science. This study
presents a new contribution of this modeling approach in oncology. Efficient
developments of new therapeutic strategies for cancer treatment require a re-
liable, robust and reproducible evaluation of therapeutic effects. In in vivo
growth inhibition studies, the most commonly used characteristics of tumor
growth are tumor growth delay (TGD) and tumor volume T/C value3. TGD
and T/C are both based on a local event, either the time instant associated
with the quadrupling of the tumor volume or the relative tumor volume at a
given time point after treatment respectively. Accordingly, these two charac-
teristics only give quantitative information about the tumor growth at an event
point but provide no information about the global behavior of the tumor after
this event. To remedy this problem, a solution consists in building parametric
models of tumor growth4–6. Those models have to be simple enough so that
they can be analyzed with available mathematical techniques, and accurate
enough to describe the important aspects of the relevant dynamical behavior.
By ’relevance’ we mean taking into consideration of three main issues raised
by tumor growth modeling.
• Choice of the response variable. The choice of the response variable to be
modeled is not obvious. In most usual tumor growth models, e.g. population
dynamics models, compartmental models or cell-cycle models, the explained
variable is the number of cancer cells in the tumor population7–14. However,
the tumor size is not easily measurable in in vivo contexts. For this reason,
in vivo tumor growth models are often based on the tumor volume that
is supposed to be proportional to the number of cancer cells7,15. However,
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Drasdo et al. showed in16–18 that tumor growth kinetics follows a power-law
growth for large times and suggested to use the tumor diameter as response
variable because of its linear growth kinetics. The in vivo tumor diameter
growth model proposed in this study is built on this assumption.
• Description of the inter-individual variability. The experiment design pro-
vides longitudinal data with few observation times but with repeated mea-
surements among subjects. Indeed in vitro as well as in vivo experiments
are always repeated to assess the reproducibility degree of the experimental
responses. In classic regression approaches, the model parameters are sup-
posed to be identical for all subjects. However, in experimental biology, the
inter-individual variability makes this assumption inappropriate. Another
approach consists in describing each model parameter as a sum of fixed and
random effects. The so-called mixed effects models (or mixed models) allow
taking into account this lack of response reproducibility. They have proved
their efficiency, particularly in biomedical applications19–21.
• Identification of influent treatment modalities. A large majority of tumor
growth models does not take into account input causes like treatment fac-
tors. As a consequence, those noncausal models are not suited to the model-
based control of anticancer treatments. Such relation of cause and effect can
be estimated in mixed models by introducing covariate effects in the expres-
sion of model parameters19.
In this study, we propose to adopt the mixed model methodology to describe
the tumor diameter growth. This suggested approach is carried out in four
successive steps:
(1) Data collection. Experimental data are time series of tumor diameters,
measured once every two days after a tumor implantation on nude mice,
using an electronic caliper. Three different therapeutic strategies for can-
4
cer treatment (radiotherapy, concomitant radiochemotherapy and pho-
todynamic therapy) are administered to three mouse groups. In the ra-
diochemotherapy mouse group, three treatment durations are compared.
(2) Choice of the model structure. We develop a model with two linear trends
and one exponential part.
(3) Parameter estimation. The parameter estimation of the mixed model is
performed with a Stochastic Approximation Expectation-Maximization
(SAEM) algorithm developed by Kuhn and Lavielle in22.
(4) Analysis of treatment effects. Treatment group covariates are introduced
in the mixed model and selected using statistical tests. Significant differ-
ences are emphasized between, on the one hand, therapeutic strategies
and, on the other hand, treatment durations in radiochemotherapy.
This paper is organized as follows. In Section 2, a new empirical kinetic model
of tumor growth is proposed. Experimental setup of data collection and statis-
tical methods are then presented in Section 3. Modeling results are analyzed
in Section 4. The case of non-treated tumor growth is firstly examined. In a
second subsection three loco-regional therapies for cancer treatment are com-
pared. Finally the estimation results for the concomitant radiochemotherapy
group to assess effects of the treatment duration are presented. The conclu-
sions and perspectives of this work are drawn in Section 5.
2 Tumor growth modeling
This Section first defines the response variable (tumor diameter). Next, we
suggest a new model structure of tumor diameter growth. To identify this
model from longitudinal data (see Figure 2(a)), a statistical mixed effects
representation is then defined. The notations used in this study are listed in
5
Table 1.
2.1 Response variable
In growth inhibition studies, the usual response variable is the tumor volume,
v(t). This quantity is defined at day t as
v(t) =
δ1(t)δ2(t)
2
2
, (1)
where δ1(t) and δ2(t) are the long and short axis dimensions, respectively, of
the ellipse formed by the tumor. δ1(t) and δ2(t) are measured every two days
in two orthogonal directions using an electronic caliper. The mean tumor
diameter could first be computed as y(t) = (δ1(t) + δ2(t))/2. Unfortunately,
δ1(t) and δ2(t), contrary to v(t), are seldom given by experimenters. That
led us to define the response variable as the diameter of a fictitious spherical
tumor of volume v,
y(t) = 3
√
6v(t)
π
. (2)
2.2 Tumor growth model structure
Treated and non-treated tumor growth responses are described by a Linear-
Exponential-Linear (LEL) model structure in which x(t) denotes the explained
diameter of the tumor at time t,
x(t) = x0
[
1 + at
︸ ︷︷ ︸
natural
growth
+
(
x1(t) + x2(t) + x3(t)
)
u
︸ ︷︷ ︸
treatment response
]
(3)
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Table 1
Main notations
Symb. Description Unit
t time day
x(t) model output (explained diameter of the tumor) mm
y(t) measured response variable (tumor mean diameter) mm
tf time of the last observation, before sacrifice of the mouse
c treatment covariate
d number of model parameters
r number of repeated experiments (nb of mice / group)
i index of the subject (mouse) with i ∈ {1, · · · , r}
n number of observations
ni number of observations for the i
th mouse
j jth observation with j ∈ {1, · · · , n}
Θ vector of the model parameters in Rd
βθ,c effect of the covariate c on the model parameter θ
Ω covariance matrix of random effects
p number of covariates
σ variance of the within-group output error
a natural diameter growth rate of the tumor day−1
b decrease rate of tumor diameter in treatment phase I day−1
k1 = b − a resulting diameter growth rate in phase I day−1
k2 slope of diameter decrease at time τ in treatment phase II
k3 decrease rate of tumor diameter in treatment phase III day
−1
τ time delay of phases II and III day
T time constant of phase II day
x0 initial value of the tumor diameter mm
PDT photodynamic therapy
RCT concomitant radiochemotherapy
RT radiotherapy
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with:
x1(t) = −b t (4)
x2(t) = −k2 T (1 − e
−(t−τ)/T ) H(t− τ) (5)
x3(t) = −k3 (t − τ) H(t− τ), (6)
where t ∈ [0; tf ]. t = 0 denotes the treatment beginning day and tf is either
sacrifice day (day at which the tumor reaches a size limit of about 15mm
diameter) or cure day (day at which the tumor is no longer perceptible, x(t) ≤
ε for t ≥ tf , ε corresponding to the minimum measurable diameter by the
caliper). u denotes the treatment variable: u = 0 for non-treated tumors and
u = 1 for treated tumors. H(t) is the Heaviside step function and x0 = x(0) is
the unknown initial value of the tumor diameter. Given (3), the tumor growth
rate ρ(t) is defined by
ρ(t) =
x(t) − x0
x0
= a t + (x1(t) + x2(t) + x3(t)) u, (7)
and can be split up into four parts:
• the natural growth phase (at) where the parameter a denotes the mean
growth rate of the tumor diameter over one day;
• the early treatment effect (x1(t)). A positive value of b denotes a mean
decrease rate of the tumor diameter over one day. a and b were gathered
into a global rate coefficient k1 = b − a to avoid identifiability problems for
treated tumors;
• the late treatment effect (x2(t)) starting at time τ , where T is a time constant
and k2 = ∂x2/∂t|t=τ corresponds to the slope of the tumor size decrease at
time τ . Those two parameters, T and τ , take into account the duration and
magnitude of the late effect;
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• the steady-state effect (x3(t)). The latter corresponds to the post-treatment
effect, where k3 denotes a mean decrease rate of the tumor diameter over
one day. At steady-state, the global growth rate is given by a− b−k3. Note
that τ both takes place in phases II and III.
As illustrated in Figure 1, kinetic effects associated with x1, x2, x3 are su-
perimposed to natural growth response to give the resultant treated growth
kinetics. From now on, Θ will denote the vector of parameters, i.e. Θ = (x0, a)
for non-treated growth kinetics and
Θ = (x0, k1, k2, T, τ, k3) (8)
for treated growth kinetics. These parameters have biological significance (ini-
tial size, diameter growth rates, time constant and time delay). Any positive
enhancement of one parameter among k1, k2, k3, T and τ suggests a local ther-
apeutic improvement during the corresponding phase of growth. Conversely,
any decrease of one of the latter parameters leads to locally degrading the
therapeutic response.
2.3 Mixed effects model
Let yij ∈ R denote the noisy measurement of tumor diameter for subject
i = 1, . . . , r at time tij with j = 1, . . . , ni and ni the number of observations
(time points) of subject i. In our case, the mixed model of the tumor growth
is given by:
yij = x(tij ,Θi) + ǫij , ∀i = 1, . . . , r, ∀j = 1, . . . , ni, (9)
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where x(tij ,Θi) is given by equation (3) and denotes the explained diameter of
subject i at time tij depending on the individual parameter vector Θi of length
d. The within-group output error ǫij is described either by a homoscedastic
error model of the type
ǫij = σ eij , eij ∼i.i.d. N (0, 1), ∀i = 1, . . . , r, ∀j = 1, . . . , ni, (10)
or a heteroscedastic error model
ǫij = σ x(tij ,Θi) eij, eij ∼i.i.d. N (0, 1), ∀i = 1, . . . , r, ∀j = 1, . . . , ni, (11)
where σ is the unknown standard error.
To take into account the inter-individual variability, the individual parameter
vectors (Θi) are assumed to be mainly Gaussian random vectors decomposed
into fixed and random effects:
Θi = λ+ ciβ + ηi, ηi ∼ N (0, Ω), ∀i = 1, . . . , r, (12)
where λ is an unknown vector of length d, called reference population pa-
rameter. β is an unknown vector of length p of covariate parameters and ci
is a covariate matrix of size d × p given by the user. Examples of covariates
used herein are presented in Section 3.3. Fixed effects are gathered in (λ, β).
ηi denotes a Gaussian vector of random effects, with covariance matrix Ω.
(eij) and (ηi) are assumed to be mutually independent. If the l-th parameter
component θil of Θi is known to be positive, e.g. x0, τ, T in equation (3), a
log parametrization is used such that log(θil) is a Gaussian variable. Model
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hyper-parameters to be estimated from experimental data are gathered in
ψ = (λ, β, Ω, σ). (13)
To simplify the presentation of the results given in Section 4, a positive value
of any fixed effect in β will denote a local improvement of the therapeutic
response due to the covariate ci and conversely a negative value will be syn-
onymous of therapeutic degradation. Thereafter, the notation βθ,c will be used
to denote the effect of the covariate c on the model parameter θ.
3 Materials and Methods
3.1 Statistical methods
3.1.1 Parameter estimation
The parameter estimation of non-linear mixed models is complex: the likeli-
hood has no explicit form because of the nonlinearity of the regression function
in the individual parameters. The Expectation-Maximization (EM) algorithm
is a generalization of the maximum likelihood estimation to the non-observed
or incomplete data case23,24. For non-linear mixed models, the non-observed
(or hidden) data are the individual parameter vector Θ = (Θ1, . . . ,Θr), the
complete data are the (y,Θ). Starting with an initial value ψ̂0 of the model
hyperparameters defined in (13), the EM algorithm seeks to find the maximum
likelihood estimate by iteratively applying the following two steps:
(1) Expectation step (E-step): calculation of the expected value of the
log likelihood function, with respect to the conditional distribution of Θ
given y under the current estimate of the parameters ψ̂m at the m-th
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iteration
Q(ψ|ψ̂m) = E(Lc(y,Θ;ψ)|y; ψ̂m) (14)
where Lc(y,Θ;ψ) is the log-likelihood of the complete data.
(2) Maximization step (M-step): update of ψ̂m by ψ̂m+1 by maximizing
this quantity
ψ̂m+1 = arg maxQ(ψ|ψ̂m) (15)
For cases in which the E-step has no analytic form, Delyon et al. introduced
in25 a stochastic version of the EM algorithm that estimates the integral
Q(ψ|ψ̂m) by a stochastic approximation procedure via the simulation of the
individual parameters Θ under the posterior distribution p(Θ|y;ψ). For non-
linear mixed models, the simulation step is not direct. Kuhn and Lavielle
proposed to use a Monte Carlo Markov Chain to simulate Θ22. They proved
the convergence of the algorithm under general hypothesis. This algorithm is
implemented in the Monolix software (http://www.monolix.org/).
3.1.2 Hypothesis testing and model selection
The estimation of the mixed model parameters is based on two main steps.
(1) The covariance matrix Ω (full or diagonal) and the output error model
ǫij (homoscedastic or heteroscedastic) are selected in a first step. This
double selection is carried out by implementing a full 22 factorial design
composed of 2 two-level factors and four combinations: (full-homo;full-
hete;diag-homo;diag-hete). Two classic information criteria: AIC (Akaike’s
Information Criterion) and BIC (Bayesian Information Criterion)26,27
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are used as selection statistics. The selected covariance matrix and er-
ror model are the ones that minimize AIC and BIC. The latter criteria
require the computation of the model log-likelihood. This log-likelihood,
which has no analytical form, is estimated using a Monte-Carlo Impor-
tance Sampling algorithm.
(2) In a second step, a Likelihood Ratio Test (LRT) is used to select covariates
β. If the LRT is not significant with a significance level of 5%, the effect
of the covariate is removed.
3.2 Experimental setup of data
Female nude mice were used for tumor implantation. Female athymic Foxn1
nude mice (nu/nu) were obtained from Harlan (Gannat, France), and used at
an age of 7-9 weeks and a weight of 20-25 g. Animal procedures were performed
according to institutional and national guidelines. The tumor, a model of
human malignant glioma (U87 cancer cell line), was maintained in vivo by
sequential passages in nude mice. For the experiments, source tumors were
excised, cleaned from necrotic tissue, cut into small chunks, and transplanted
subcutaneously in the hind leg of each mouse. Three loco-regional therapies
for cancer treatment were carried out: RT (radiotherapy), RCT (concomitant
radiochemotherapy) and PDT (photodynamic therapy).
A group of 54 mice did not receive any treatment and was considered as the
control group.
Radiotherapy was applied during 6 weeks to a group of 7 mice with a total dose
of 40Gy per mouse for ionizing radiation. Concomitant radiochemotherapy was
delivered during 1, 2, 4 or 6 weeks to groups of 7 mice. RCT was based on the
combination of topotecan (daily intraperitoneal injection, 5 days/week) and
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ionizing radiation (5 days/week). Total doses were 3mg/kg for topotecan and
40Gy for ionizing radiation. RT and RCT treatments started when tumors
reached a mean diameter of 8 ± 1 mm.
For the PDT group, tumors were treated when they reached a size of 5±1mm
mean diameter. A new targeted photosensitizing agent, a chlorin conjugated to
heptapeptide targeting neuropilin-1, was used28. The in vivo treatment condi-
tion was: drug-light interval: 4 hrs, agent dose: 2.80 mg/kg, fluence: 120 J/cm2
and fluence rate: 85 mW/cm2. The PDT group was composed of 8 mice.
The complete biological and medical protocols are defined in29,30. For each
subject, the observation period started at the beginning of treatment (t = 0).
Measurements were then carried out until the tumors reached a size of 15mm
in diameter, the legal barrier at which time the mice were sacrificed by cervical
dislocation.
3.3 Comparative studies in oncology
Three cases were examined in this study:
• Treated and not-treated (control) tumors. Results of non-treated tumor
growth identification are presented in Section 4.1.
• Three therapeutic strategies for cancer treatment (RT, RCT, PDT). Treat-
ments RCT and PDT were encoded by binary covariates taking value 1 when
the therapy was applied and 0 otherwise, RT being the reference treatment.
Results are presented in Section 4.2.
• Four different treatment durations for the concomitant radiochemotherapy:
1, 2, 4, 6 weeks for constant total doses of drug and radiation. This treatment
duration was described by a categorical covariate discretized into four levels:
14
{1, 2, 4, 6}. Results are presented in Section 4.3.
4 Results
The results of the non-treated tumor growth are presented first. Then the com-
parison of the three treatments is detailed. Finally, the effect of the treatment
duration in concomitant radiochemotherapy is identified.
4.1 Non-treated tumor growth identification
The model selection procedure, presented in Section 3.1.2 and based on the
minimization of AIC and BIC, applied to the natural growth responses of
U87-tumors (u = 0) has led to opting for the homoscedastic error model and
a diagonal covariance matrix Ω (AIC = 1413, BIC = 1423).
Estimates of the model parameters are given in Table 2. In Figure 2, the em-
pirical distributions of the equation residuals (e) and their quantile-quantile
plot confirm the Gaussian assumption stated in (10). A comparison of pre-
dicted responses with observations for a few subjects of the U87 control group
is displayed in Figure 3(a). The linear trend of the diameter growth is mani-
fest. In other terms, the linearity assumption about the natural tumor growth
is corroborated by the present results.
4.2 Treated tumor growth identification and comparison of the three loco-
regional therapies
In vivo data of three loco-regional therapies - radiotherapy (RT), concomi-
tant radiochemotherapy (RCT) and photodynamic therapy (PDT)- were an-
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alyzed. In the model selection procedure, AIC and BIC criteria were minimal
for homoscedastic error model (ǫij) and a diagonal covariance matrix Ω with
Ω = diag(ωx0, ωT , ωk1, ωτ , ωk2, ωk3). Then the three treatment effects were com-
pared with each other. The selection of the influent covariates, among RCT
and PDT, on (x0, k1, k2, T, τ, k3) was then applied using the method detailed in
Section 3.1.2. The final model (AIC = 939) included five significant covariate
effects: four effects due to PDT (βx0,PDT , βk1,PDT , βk2,PDT , βk3,PDT ) on param-
eters x0, k1, k2, k3 respectively and one effect induced by RCT, βτ,RCT , on the
time delay τ . Parameter values are presented in Table 3. βx0,PDT = −2.73 mm,
is particular and should not be compared with the other fixed effects. Indeed,
it represents the significant variations of the tumor initial size x0 between
groups of mice, which are about 3mm in this study case (see Experimental
setup of data in Section 3.2).
The results emphasize that the three therapies lead to reducing the growth rate
of tumors during the first phase in comparison with natural growth responses
(k1 < a where the natural growth rate a is given in Table 2). The positive value
of βk1,PDT reveals an improved therapeutic efficiency (growth rate reduction) of
PDT compared to RT and RCT during this phase. Conversely, RCT produces
better therapeutical effects than PDT during the second phase as illustrated
in Figure 3(c). Indeed, RT and RCT cause a transient decrease of the tumor
diameter (k2 > 0) during the second phase while PDT leads to an opposite
effect (βk2,PDT < 0), i.e. a momentary increase of tumor size over the same
period of time. The RCT treatment also reveals a positive effect βτ,RCT on the
time delay τ , meaning that RCT significantly defers tumor growth compared
to RT and PDT. At steady-state of growth (late effect), the positive effect of
PDT on the decrease rate k3 of the tumor diameter indicates that PDT better
limits the growth rate than RT and RCT during that period of time. These
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different previous effects can be observed in the experimental and predicted
growth responses for a few mice treated by the three therapies, see Figure 3.
Table 4 displays the correlation matrix of the parameter estimates, whose the
content confirms the independence assumption between the model parameters.
These results emphasize the practical interest of such a model-based approach
to characterize, analyze and compare anti-cancer therapeutic responses by
using model parameters as therapeutic outcome indicators.
4.3 Evaluation of the treatment-duration effect for the concomitant radioche-
motherapy
The last question was to estimate the effect of the treatment duration on
growth of tumors treated by concomitant radiochemotherapy. The model se-
lection strategy was applied as described in Section 3.1.2, a homoscedastic
error model and a diagonal covariance matrix were selected. The final model
only includes covariates on parameters k2 and τ : βk2,2, βτ,4, βτ,6. The second
indices 2, 4, 6 of the covariate effects denote values of the treatment duration.
Parameter values are presented in Table 5 and Table 6 displays the correlation
matrix of the parameter estimates. As previously, the estimated correlation
coefficients confirm the independence assumption between the model param-
eters. The positive value of k2 confirms the transient decrease of the tumor
diameter in the second phase. The 2-week treatment duration increases the
positive effect, βk2,2, on this transient decrease while there is no significant
effect for the 4- and 6-week treatment durations. The treatment duration has
also a significant effect on τ , estimated by βτ,4 and βτ,6. The longer the treat-
ment, the more the tumor growth is delayed. Therefore, those two indicators
allow the biologist to select the suited treatment modalities in order to opti-
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mize the therapeutic response. In this case, adding the total dose of radiation
D to the factors of the experimental design could bring new insight into the
therapeutic effects of the treatment.
5 Conclusion
This paper proposes a new mixed effects model for diameter growth of treated
and non-treated tumors. Compared to classic tumor volume models, its main
advantage is the simplicity of its kinetic structure. Model parameters, com-
posed of growth rates, growth delays or time constants are meaningful. They
characterize the early, late and steady-state effects of anti-cancer treatments.
In vivo results confirmed the relevance of the suggested model to describe the
tumor growth responses to three loco-regional anti-cancer treatments. The
main advantage of the mixed effects models is to introduce treatment factors
into the model, e.g. the treatment duration, in order to estimate their influence
on tumor growth while taking into account the inter-individual variability of
in vivo growth responses. The presented results highlight the potential role of
the parameter estimates as therapeutic outcome indicators. The application
of the Linear-Exponential-Linear model structure to other cancer cell lines is
currently in progress. A simplified version of this model, reduced to the steady-
state phase of growth, was recently used to optimize treatment modalities of
PDT31. Indeed, the main application of such a model is the optimization of
anti-cancer treatment modalities by its combined use with optimal experiment
designs, e.g. as proposed by Retout et al. in32 for mixed models optimal design.
In this perspective, all potential factors of treatment have to be considered in
the experimental design.
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17 Drasdo D, Höhme S. A single-cell-based model of tumor growth in vitro:
monolayers and spheroids. Phys Biol. 2005;2:133–147.
18 Galle J, Aust G, Schaller G, Beyer T, Drasdo D. Individual cell-based mod-
els of the spatio-temporal organisation of multicellular systems - achieve-
ments and limitations. Cytometry, Cytometry A. 2006;69A:704–710.
19 Lindstrom M, Bates D. Nonlinear mixed-effects models for repeated mea-
sures data. Biometrics. 1990;46:673–687.
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Figure 1. L- and LEL-model structures of the tumor diameter growth (LEL: linear–
exponential-linear). tg denotes the grafting time.
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Table 2
Parameter estimates and their standard errors (s.e.) for the non-treated tumor
growth modeling. ωa and ωx0 are diagonal elements of the covariance matrix Ω
defined in (12)
param. estimate (s.e.)
x0 [mm] 5.95 ( 0.22)
a [day−1] 0.0604 (0.0025)
ωa 0.0166 (0.01)
ωx0 0.264 (0.01)
σ 0.558 (0.018)
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Figure 2. Longitudinal data set and residual analysis for the U87 control group
25
Table 3
Parameter estimates, standard errors (s.e.) and p-values of the Wald test of the
LEL-model parameters for three loco-regional therapies: RT, RCT and PDT (radio-
therapy, concomitant radiochemotherapy and photodynamic therapy). Estimates of
(x0, k1, k2, T, τ, k3) are values of λ (see Eq. 12) determined by the SAEM algorithm.
Only significant covariate effects are presented.
parameter estimate (s.e.) parameter estimate (s.e.) p-value
x0 [mm] 7.9 (0.12) βx0,PDT -2.73 (0.2) < 10
−10
k1 [day
−1] -0.0394 (0.005) βk1,PDT 0.0451 (0.0096) 2.7e − 6
k2 [day
−1] 0.0387 (0.015) βk2,PDT -0.0633 (0.025) 0.011
T [day] 8.54 (2.7)
τ [day] 10.3 (1.2) βτ,RCT 6.53 (2.1) 0.0021
k3 [day
−1] -0.015 (0.0096) βk3,PDT 0.0642 (0.016) 5.2e-05
ωx0 0.317 (0.092) ωT 3.02 (4.2)
ωk1 0.0177 (0.0032) ωτ 4.2 (0.74)
ωk2 0.0449 (0.0094) ωk3 0.0297 (0.0056)
σ 0.484 (0.019)
Table 4
Correlation matrix of the estimates for three loco-regional therapies: RT, RCT and
PDT (radiotherapy, concomitant radiochemotherapy and photodynamic therapy).
x0 βx0,PDT k1 βk1,PDT k2 βk2,PDT T τ βτ,RCT k3 βk3,PDT
x0 1
βx0,PDT -0.58 1
k1 -0.22 0.14 1
βk1,PDT -0.31 0.12 -0.54 1
k2 -0.06 0.03 0.04 -0.01 1
βk2,PDT 0.03 0 -0.02 0.01 -0.6 1
T -0.01 0.01 0.01 -0.02 -0.08 0.13 1
τ 0.02 -0.05 -0.03 0.11 0.07 -0.13 -0.07 1
βτ,RCT 0.03 0 -0.02 -0.04 -0.01 0.05 -0.05 -0.56 1
k3 0.09 -0.05 -0.06 0.03 0.17 -0.08 0.31 0.03 -0.01 1
βk3,PDT -0.05 0.14 0.04 -0.17 -0.1 0.14 -0.27 -0.09 0.06 -0.63 1
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Table 5
Parameter estimates, standard errors (s.e.) and p-values of the Wald test of the
LEL-model parameters for three concomitant radiochemotherapy. Estimates of
(x0, k1, k2, T, τ, k3) are values of λ (see Eq. 12) determined by the SAEM algorithm.
Only significant covariate effects are presented. Indices 2, 4, 6 of the covariate effects
denote values of the treatment duration (see Section 3.3).
parameter estimate (s.e.) parameter estimate (s.e.) p-value
x0 [mm] 8.04 (0.13)
k1 [day
−1] -0.0171 (0.0014)
k2 [day
−1] 0.0438 (0.0044) βk2,2 0.0203 (0.0093) 0.029
T [day] 10.8 (2.1)
τ [day] 14.7 (0.64) βτ,4 3.92 (1) 0.00016
βτ,6 7.06 (1) 1.1e-11
k3 [day
−1] 0.00762 (0.0032)
ωx0 0.6 (0.094) ωT 2.07 (3)
ωk1 0.0061 (0.0011) ωτ 1.6 (0.4)
ωk2 0.0169 (0.0032) ωk3 0.00987 (0.0019)
σ 0.449 (0.013)
27
Table 6
Correlation matrix of the estimates for three modalities of concomitant ra-
diochemotherapy.
x0 k1 k2 βk2,2 T τ βτ,4 βτ,6 k3
x0 1
k1 -0.2 1
k2 -0.07 0.12 1
βk2,2 -0.01 0.02 -0.47 1
T 0 0.01 0.19 -0.11 1
τ 0.05 -0.15 -0.03 0.06 -0.28 1
βτ,4 0 0.03 0.06 -0.05 0.03 -0.58 1
βτ,6 -0.01 0.04 0.05 -0.05 0.04 -0.61 0.39 1
k3 0.05 -0.08 0.27 -0.11 0.83 -0.15 0.02 0.02 1
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(d) Photodynamic therapy responses
Figure 3. Diameter growth kinetics of U87 tumors and predicted responses. Four
growth kinetics are shown for each study case. The first row (a) exhibits the lin-
ear growth of the tumor diameter for the control (non-treated) group. The second
row (b) displays the therapeutical responses of the radiotherapy where the early
and late effects of the treatment clearly appear. The responses of the concomitant
radiochemotherapy are presented in the third row (c). They express a larger late
effect, characterized by a deeper decrease of the tumor diameters, than for the ra-
diotherapy treatment. The last row (d) shows the photodynamic therapy responses.
They particularly point out an improved early effect of the treatment and more
precisely a significant reduction of the growth rate during the first phase. A total
cure is observed in the last figure. In all cases, the predicted responses provided
by the model are close to the observed growth kinetics, whatever the anticancer
treatment used.
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